Well spotted Philley.
A couple of other points as well.
"In current Phase 1b breast & ovarian cancer trials for PTX-200, interim
analysis showed encouraging efficacy."
And....
"Multiple milestone announcements and valuation inflection points
across all clinical programs in 2017".
Has PTX the treatment that many have hoped, need and being waiting for?
Time will tell, luck to recipients and holders alike.
PTX Price at posting:
9.4¢ Sentiment: Hold Disclosure: Held
